Title: Stabilized FGF Formulations Containing Reducing Agents
Invertor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Pation No: Not yet assigned
Att. 1. No: PP16021.002 (35784/213736)

# Liquid rFGF-2 Formulations CN-RP-HPLC % Main Peak 4°C




Figure 1

Title: Stabilized FGF Formulations Containing Reducing Agents
Legator(s): Robert V. Hageman, Bret A. Shirley, Kamaljit Korva
cation No: Not yet assigned
Dkt No: PP16021.002 (35784/213736)

# rFGF-2 Liquid Formulations CN-RP-HPLC % Main Peak 17°C




Figure 2

Title: Stabilized FGF Formulations Containing Reducing Agents Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa Application No: Not yet assigned

# rFGF-2 Liquid Formulations CN-RP-HPLC % Main Peak 30°C





Figure 3

#### Licid rFGF-2 Formulaions % Main Peak **CN-RP-HPLC** 30°C




- 0.5% Acetyl Cysteine / 10 mM DTT pH 5.5
- 0.5% Acetyl Cysteine pH 6.0
- \_O ⋅ 10 mM DTT pH 6.0
- 0.5% Acetyl Cysteine / 10 mM DTT pH 6.0
- —∆— 0.5% Acetyl Cysteine pH 6.5
- -C>- 0.5% Acetyl Cysteine / 10 mM DTT pH 6.5

Figure 4

Title: Stabilized FGF Formulations Containing Reducing Agents Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa Atty Dkt No: PP16021.002 (35784/213736) Application No: Not yet assigned

### Lyophized rFGF-2 Formulations CN-RP-HPLC % Main Peak 40°C




- 0% Acetyl Cysteine / 0 mM DTT pH 5.5
- 0.5% Acetyl Cysteine pH 5.5
- \_\_\_ · 10 mM DTT pH 5.5
- ——— 0.5% Acetyl Cysteine / 10 mM DTT pH 5.5
- 0.5% Acetyl Cysteine pH 6.0
- \_\_\_\_\_\_ 10 mM DTT pH 6.0
- 0.5% Acetyl Cysteine / 10 mM DTT pH 6.0
- $\triangle$  0.5% Acetyl Cysteine pH 6.5
- $\rightarrow$  10 mM DTT pH 6.5
- -0.5% Acetyl Cysteine / 10 mM DTT pH 6.5

Figure 5

All formulations contain:

10 mM sodium citrate 2% glycine 1% sucrose 1 mM EDTA Title: Stabilized FGF Formulations Containing Reducing Agents Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa Application No: Not yet assigned Atty Dkt No: PP16021.002 (35784/213736)

#### Lyophnized rFGF-2 Formulations CN-RP-HPLC % Main Peak 50°C



- 0% Acetyl Cysteine / 0 mM DTT pH 5.5
- ——— 0.5% Acetyl Cysteine pH 5.5
- \_\_\_\_ 10 mM DTT pH 5.5
- 0.5% Acetyl Cysteine / 10 mM DTT pH 5.5
- 0.5% Acetyl Cysteine pH 6.0
- \_O 10 mM DTT pH 6.0
- -[] 0.5% Acetyl Cysteine / 10 mM DTT pH 6.0
- -∆- 0.5% Acetyl Cysteine pH 6.5
- -√- 10 mM DTT pH 6.5
- 0.5% Acetyl Cysteine / 10 mM DTT pH 6.5

#### Weeks

Figure 6

All formulations contain:

10 mM sodium citrate 2% glycine 1% sucrose 1 mM EDTA Title: Stabilized FGF Formulations Containing Reducing Agents Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa Application No: Not yet assigned Atty Dkt No: PP16021.002 (35784/213736)

Ventor(s): Robert V. Hageman, Bret A. Shirley, Kamalja Bajwa Application No: Not yet assigned Atty Dkt No: PP16021.002 (35784/213736)

## rhFGF2 Stability 30°C RP-HPLC % Main Peak

